Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib

BACKGROUND: The receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK) has been implicated in the tumorigenesis of rhabdomyosarcoma (RMS). However, the exact role of ALK in RMS is debatable and remains to be elucidated. OBJECTIVE: To determine the in vitro and in vivo effects and mechanism...

Descripción completa

Detalles Bibliográficos
Autores principales: van Erp, Anke E. M., Hillebrandt-Roeffen, Melissa H. S., van Houdt, Laurens, Fleuren, Emmy D. G., van der Graaf, Winette T. A., Versleijen-Jonkers, Yvonne M. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700232/
https://www.ncbi.nlm.nih.gov/pubmed/29067644
http://dx.doi.org/10.1007/s11523-017-0528-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700232/
https://www.ncbi.nlm.nih.gov/pubmed/29067644
http://dx.doi.org/10.1007/s11523-017-0528-z

Ejemplares similares